Deleted Tweets From Scott Gottlieb, R-D.C.

With the changing standard of care towards transformative immuno-oncology products across many areas of cancer, #FDA is evaluating immune-based criteria and the potential for these to serve as the primary evidence to support approval of novel cancer drugs https://t.co/EXmo51XmJj

RT @NASEM_Health: Tomorrow, tune in to the open session of our study on evidence-based clinical practice guidelines for prescribing #opioids for acute pain, featuring comments from @SGottliebFDA. Registration

RT @SecAzar: Grateful to witness yesterday's #VeteransDay ceremony at Arlington Cemetery to thank and honor all who served in the U.S. armed forces. We were privileged to have members of the U.S. Public H

RT @FDAfood: This year FDA kicked off #Veterans Viewpoint, a virtual recruitment effort dedicated to serving veterans & persons… https://t.co/JFUbZ5gZXX

Meet #FDAOncology and other FDA staff and learn about opportunities for patient advocacy at our 2nd annual educational workshop for new cancer patient advocates, Partners in Progress #OCEPIP18 https://t.co/6ufnpsia5y

RT @FDA_Track: U.S. regulators snip red tape for medical devices to curb #opioid crisis... https://t.co/n1tO7TMBdA

As part of our commitment to the development of countermeasures, #FDA announced an EUA for the first Ebola rapid antigen fingerstick test that uses a portable reader that can help provide clear diagnostic results in austere settings like field operations: https://t.co/L8GTWnmCn0 https://t.co/tG1lSaGEEY

RT @SecAzar: Thankful to have veterans like Stephanie continuing their service to our country at @HHSGov. Across the department, there are almost 6,000 veterans working every day to improve the health and

RT @Surgeon_General: We need to do more & we CAN do more. I recently released a 21st century advisory to educate all individuals about the opioid crisis. The digital postcard provides steps anyone can take to

RT @postlive: . @SGottliebFDA addresses restrictions on the sale of certain types of flavored e-cigarettes that are getting in the hands of teenagers. https://t.co/YvruCKSw5X

RT @postlive: .@SGottliebFDA talks about the challenges facing oncologists and cancer patients when it comes to prescribing opioids to manage chronic pain in the midst of the scrutiny around the national o

RT @NASEM_Health: FDA Commissioner @SGottliebFDA addresses our committee on evidence-based clinical practice guidelines for prescribing #opioids for acute pain. Learn more about the study: https://t.co/U8ECtuT

#FDA is committed to fostering the development of novel therapies to treat and prevent prostate cancer. Today, we issued guidance to industry on using metastasis-free survival endpoints in clinical trials: https://t.co/65opOhsHtv https://t.co/Dab1EtYjbT

THREAD: Today I spoke at @NASEM_Health’s kick-off meeting for its work related to #FDA’s efforts to help advance the development of evidence-based, indication-specific guidelines for appropriate opioid prescribing for acute pain: https://t.co/XWXAr4iKLV https://t.co/MfkHfvnJAc

Not only can these endpoints be a predictor of overall survival, but they can be critical to showing an investigational drug is effective.

Reducing unnecessary exposure is key to reducing the risk of new addiction. This work is a new phase in our efforts to combat America’s epidemic of opioid addiction & is just one of a number of new steps we’re taking to expand our work to forcefully confront the opioid crisis.

We also need to focus more attention on the strength of the dose of the opioids that are being used, and the total exposure a patient receives -- measured by total daily dose of opioids that patients get. These considerations impact the risk of developing dependency and addiction

We plan to put more focus on duration of use and doses of opioids, incl. plans for new steps to require some immediate-release opioids be made available in unit of dose packaging like blister packs. This can be an effective way to make shorter duration prescription more common.

But even as we take more aggressive measures to curtail new addiction and help those currently addicted transition to lives of sobriety we must still ensure proper care for those who suffer chronic pain, and for whom opioid analgesics are sometimes the only effective alternative

RT @FDASpox: Hiring great candidates is one way FDA is trying to make a difference in cancer research. Learn about open positions at FDA here: https://t.co/ScTCALM3iv and follow @FDAJobs. https://t.co/3YC

With the changing standard of care towards transformative immuno-oncology products across many areas of cancer, #FDA is evaluating immune-based criteria and the potential for these to serve as the primary evidence to support approval of novel cancer drugs https://t.co/EXmo51XmJj

RT @NASEM_Health: Tomorrow, tune in to the open session of our study on evidence-based clinical practice guidelines for prescribing #opioids for acute pain, featuring comments from @SGottliebFDA. Registration

RT @SecAzar: Grateful to witness yesterday's #VeteransDay ceremony at Arlington Cemetery to thank and honor all who served in the U.S. armed forces. We were privileged to have members of the U.S. Public H

RT @FDAfood: This year FDA kicked off #Veterans Viewpoint, a virtual recruitment effort dedicated to serving veterans & persons… https://t.co/JFUbZ5gZXX

Meet #FDAOncology and other FDA staff and learn about opportunities for patient advocacy at our 2nd annual educational workshop for new cancer patient advocates, Partners in Progress #OCEPIP18 https://t.co/6ufnpsia5y

RT @FDA_Track: U.S. regulators snip red tape for medical devices to curb #opioid crisis... https://t.co/n1tO7TMBdA

As part of our commitment to the development of countermeasures, #FDA announced an EUA for the first Ebola rapid antigen fingerstick test that uses a portable reader that can help provide clear diagnostic results in austere settings like field operations: https://t.co/L8GTWnmCn0 https://t.co/tG1lSaGEEY

RT @SecAzar: Thankful to have veterans like Stephanie continuing their service to our country at @HHSGov. Across the department, there are almost 6,000 veterans working every day to improve the health and

RT @Surgeon_General: We need to do more & we CAN do more. I recently released a 21st century advisory to educate all individuals about the opioid crisis. The digital postcard provides steps anyone can take to

RT @postlive: . @SGottliebFDA addresses restrictions on the sale of certain types of flavored e-cigarettes that are getting in the hands of teenagers. https://t.co/YvruCKSw5X

RT @postlive: .@SGottliebFDA talks about the challenges facing oncologists and cancer patients when it comes to prescribing opioids to manage chronic pain in the midst of the scrutiny around the national o

RT @NASEM_Health: FDA Commissioner @SGottliebFDA addresses our committee on evidence-based clinical practice guidelines for prescribing #opioids for acute pain. Learn more about the study: https://t.co/U8ECtuT

#FDA is committed to fostering the development of novel therapies to treat and prevent prostate cancer. Today, we issued guidance to industry on using metastasis-free survival endpoints in clinical trials: https://t.co/65opOhsHtv https://t.co/Dab1EtYjbT

THREAD: Today I spoke at @NASEM_Health’s kick-off meeting for its work related to #FDA’s efforts to help advance the development of evidence-based, indication-specific guidelines for appropriate opioid prescribing for acute pain: https://t.co/XWXAr4iKLV https://t.co/MfkHfvnJAc

Not only can these endpoints be a predictor of overall survival, but they can be critical to showing an investigational drug is effective.

Reducing unnecessary exposure is key to reducing the risk of new addiction. This work is a new phase in our efforts to combat America’s epidemic of opioid addiction & is just one of a number of new steps we’re taking to expand our work to forcefully confront the opioid crisis.

We also need to focus more attention on the strength of the dose of the opioids that are being used, and the total exposure a patient receives -- measured by total daily dose of opioids that patients get. These considerations impact the risk of developing dependency and addiction

We plan to put more focus on duration of use and doses of opioids, incl. plans for new steps to require some immediate-release opioids be made available in unit of dose packaging like blister packs. This can be an effective way to make shorter duration prescription more common.

But even as we take more aggressive measures to curtail new addiction and help those currently addicted transition to lives of sobriety we must still ensure proper care for those who suffer chronic pain, and for whom opioid analgesics are sometimes the only effective alternative

RT @FDASpox: Hiring great candidates is one way FDA is trying to make a difference in cancer research. Learn about open positions at FDA here: https://t.co/ScTCALM3iv and follow @FDAJobs. https://t.co/3YC